In This Article:
LONDON, Ontario and BOSTON - (NewMediaWire) - October 11, 2024 - Experienced leadership team positions company to advance Cell Pouch(TM) bio-hybrid organ programs. - Sernova Corp. (TSX: SVA) (OTCQB: SEOVF) (FSE/XETRA: PSH), a leading regenerative medicine company currently executing a phase 1/2 clinical study with its' Cell Pouch(TM) bio-hybrid organ in type 1 diabetes is pleased to announce key new appointments to its executive leadership team. This strategic move reflects Sernova's commitment to enhancing communication with stakeholders and corporate governance, as the company drives its' innovative research and ongoing clinical development programs.
James Parsons has been named Chief Financial Officer (CFO), bringing over 20 years of financial management experience to the team. With a comprehensive track record in biotech corporate finance, governance and strategic planning, Mr. Parsons will lead Sernova's finance team and ensure the company's financial strength to support expanding objectives.
Joining as Chief Communications Officer (CCO) is Marylyn Rigby, an accomplished professional with a rich history in branding, corporate communications and biotech and health tech marketing. Ms. Rigby will direct Sernova's comprehensive communication strategies, enhancing marketing initiatives, expanding media relationships, and elevating investor and stakeholder engagement, pivotal for bolstering Sernova's brand identity and outreach.
David Burke assumes the role of Vice President of Investor Relations, tasked with fortifying connections with the investment community. Bringing extensive experience in investor communications and financial markets, Mr. Burke will ensure transparent, timely, and effective dialogue with current and prospective investors, building trust and fostering long-term support for Sernova's visionary projects.
Jonathan Rigby, CEO of Sernova Corp., expressed his enthusiasm for the appointments, stating, "We are thrilled to welcome James, Marylyn, and David to our leadership team. Each brings a unique set of skills and deep industry knowledge that will be vital as we continue to advance our pipeline and expand our corporate presence. Their expertise aligns perfectly with our mission to Give Patients Their Lives Back through our groundbreaking therapies."
These key appointments exemplify a step change in Sernova's unwavering commitment to excellence and innovation as it continues to drive forward novel treatments that aim to transform how chronic conditions are treated in order to improve the lives of patients, their families, and their caregivers.